{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:40:52Z","timestamp":1784551252852,"version":"3.55.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 CA 009599"],"award-info":[{"award-number":["T32 CA 009599"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Clinics of North America"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.suc.2024.03.004","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T16:34:44Z","timestamp":1713285284000},"page":"1017-1030","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Locally Advanced Pancreas Cancer, Is There a Role for Surgery?"],"prefix":"10.1016","volume":"104","author":[{"given":"Brittany C.","family":"Fields","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Wei D.","family":"Tzeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.suc.2024.03.004_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"20","key":"10.1016\/j.suc.2024.03.004_bib3","article-title":"Currently debated topics on surgical treatment of pancreatic ductal adenocarcinoma: a narrative review on surgical treatment of borderline resectable, locally advanced, and synchronous or metachronous oligometastatic tumor","volume":"12","author":"Pedrazzoli","year":"2023","journal-title":"J\u00a0Clin Med"},{"issue":"4","key":"10.1016\/j.suc.2024.03.004_bib4","doi-asserted-by":"crossref","first-page":"e1000267","DOI":"10.1371\/journal.pmed.1000267","article-title":"Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages","volume":"7","author":"Gillen","year":"2010","journal-title":"PLoS Med"},{"issue":"9","key":"10.1016\/j.suc.2024.03.004_bib5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: a review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.suc.2024.03.004_bib6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1200\/JOP.2016.017376","article-title":"Locally advanced unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary","volume":"13","author":"Balaban","year":"2017","journal-title":"J\u00a0Oncol Pract"},{"issue":"16","key":"10.1016\/j.suc.2024.03.004_bib7","first-page":"11","article-title":"Advances and remaining challenges in the treatment for borderline resectable and locally advanced pancreatic ductal adenocarcinoma","author":"Sulciner","year":"2022","journal-title":"J\u00a0Clin Med"},{"issue":"5","key":"10.1016\/j.suc.2024.03.004_bib8","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3322\/caac.21626","article-title":"Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma","volume":"70","author":"Grossberg","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.suc.2024.03.004_bib9","article-title":"Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer","author":"Stoop","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.suc.2024.03.004_bib10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1053\/j.seminoncol.2021.02.005","article-title":"Radiotherapy for locally advanced pancreatic ductal adenocarcinoma","volume":"48","author":"Buss","year":"2021","journal-title":"Semin Oncol"},{"issue":"8","key":"10.1016\/j.suc.2024.03.004_bib11","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1245\/ASO.2006.08.011","article-title":"Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy","volume":"13","author":"Varadhachary","year":"2006","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.suc.2024.03.004_bib12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.semradonc.2013.11.006","article-title":"Management of borderline resectable pancreatic cancer","volume":"24","author":"Katz","year":"2014","journal-title":"Semin Radiat Oncol"},{"issue":"5","key":"10.1016\/j.suc.2024.03.004_bib13","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.21037\/jgo-2020-slapc-04","article-title":"Resectable, borderline, and locally advanced pancreatic cancer-\"the good, the bad, and the ugly\" candidates for surgery?","volume":"12","author":"Bratlie","year":"2021","journal-title":"J\u00a0Gastrointest Oncol"},{"issue":"19","key":"10.1016\/j.suc.2024.03.004_bib14","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.suc.2024.03.004_bib15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S2468-1253(19)30327-9","article-title":"Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study","volume":"5","author":"Philip","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.suc.2024.03.004_bib16","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2468-1253(20)30330-7","article-title":"Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial","volume":"6","author":"Kunzmann","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.suc.2024.03.004_bib17","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.21873\/anticanres.12692","article-title":"Neoadjuvant Nab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX","volume":"38","author":"Peterson","year":"2018","journal-title":"Anticancer Res"},{"issue":"17","key":"10.1016\/j.suc.2024.03.004_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174326","article-title":"Efficacy and safety of neoadjuvant gemcitabine plus nab-paclitaxel in borderline resectable and locally advanced pancreatic cancer-a systematic review and meta-analysis","volume":"13","author":"Damm","year":"2021","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.suc.2024.03.004_bib19","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1245\/s10434-023-13353-2","article-title":"FOLFIRINOX or gemcitabine-based chemotherapy for borderline resectable and locally advanced pancreatic cancer: a multi-institutional, patient-level, meta-analysis and systematic review","volume":"30","author":"Eshmuminov","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.suc.2024.03.004_bib20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/SLA.0000000000004155","article-title":"Surgical outcome results from SWOG S1505: a randomized clinical trial of mfolfirinox versus gemcitabine\/nab-paclitaxel for perioperative treatment of resectable pancreatic ductal adenocarcinoma","volume":"272","author":"Ahmad","year":"2020","journal-title":"Ann Surg"},{"issue":"8","key":"10.1016\/j.suc.2024.03.004_bib21","doi-asserted-by":"crossref","first-page":"e161137","DOI":"10.1001\/jamasurg.2016.1137","article-title":"Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101","volume":"151","author":"Katz","year":"2016","journal-title":"JAMA Surg"},{"key":"10.1016\/j.suc.2024.03.004_bib22","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3389\/fonc.2020.00516","article-title":"Response to preoperative therapy in localized pancreatic cancer","volume":"10","author":"Perri","year":"2020","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.suc.2024.03.004_bib23","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.suc.2024.03.004_bib24","doi-asserted-by":"crossref","first-page":"e615","DOI":"10.1016\/j.ijrobp.2011.04.045","article-title":"Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer","volume":"81","author":"Mahadevan","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.suc.2024.03.004_bib25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijrobp.2010.05.006","article-title":"Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer","volume":"81","author":"Schellenberg","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"10.1016\/j.suc.2024.03.004_bib26","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1002\/cncr.26633","article-title":"Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer","volume":"118","author":"Arvold","year":"2012","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.suc.2024.03.004_bib27","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1002\/cncr.30780","article-title":"Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer","volume":"123","author":"Torgeson","year":"2017","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.suc.2024.03.004_bib28","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/SLA.0000000000002705","article-title":"Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2\/3 trial","volume":"268","author":"Jang","year":"2018","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.suc.2024.03.004_bib29","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1245\/s10434-018-6931-6","article-title":"How does chemoradiotherapy following induction FOLFIRINOX improve the results in resected borderline or locally advanced pancreatic adenocarcinoma? An AGEO-FRENCH multicentric cohort","volume":"26","author":"Pietrasz","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.suc.2024.03.004_bib30","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/bjs\/znac002","article-title":"Comparing neoadjuvant chemotherapy with or without radiation therapy for pancreatic ductal adenocarcinoma: National Cancer Database cohort analysis","volume":"109","author":"Oba","year":"2022","journal-title":"Br J Surg"},{"issue":"7","key":"10.1016\/j.suc.2024.03.004_bib31","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jamaoncol.2018.0329","article-title":"Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial","volume":"4","author":"Murphy","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.suc.2024.03.004_bib32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12885-021-09095-7","article-title":"PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer","volume":"22","author":"Douglas","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.suc.2024.03.004_bib33","article-title":"ASO author reflections: nationwide experience on locally advanced pancreatic cancer surgery after induction chemotherapy in the netherlands: a stepping stone for the PREOPANC-4 Trial","author":"Stoop","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.suc.2024.03.004_bib34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.21037\/cco.2017.06.17","article-title":"Multimodality management of borderline resectable pancreatic adenocarcinoma","volume":"6","author":"Prakash","year":"2017","journal-title":"Chin Clin Oncol"},{"issue":"1","key":"10.1016\/j.suc.2024.03.004_bib35","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12957-017-1240-2","article-title":"Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients","volume":"15","author":"Dhir","year":"2017","journal-title":"World J Surg Oncol"},{"issue":"2","key":"10.1016\/j.suc.2024.03.004_bib36","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/SLA.0000000000002753","article-title":"Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection","volume":"270","author":"Gemenetzis","year":"2019","journal-title":"Ann Surg"},{"issue":"16","key":"10.1016\/j.suc.2024.03.004_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15164174","article-title":"Surgical considerations for neoadjuvant therapy for pancreatic adenocarcinoma","volume":"15","author":"Jain","year":"2023","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.suc.2024.03.004_bib38","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1245\/s10434-021-10991-2","article-title":"Neoadjuvant chemotherapy switch in borderline resectable\/locally advanced pancreatic cancer","volume":"29","author":"Alva-Ruiz","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.suc.2024.03.004_bib39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","article-title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial","volume":"8","author":"Ghaneh","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.suc.2024.03.004_bib40","article-title":"ASO practice guidelines series: management of resectable, borderline resectable, and locally advanced pancreas cancer","author":"Turner","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.suc.2024.03.004_bib41","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41571-023-00746-1","article-title":"Neoadjuvant therapy for pancreatic cancer","volume":"20","author":"Springfeld","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.suc.2024.03.004_bib42","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jamcollsurg.2020.05.005","article-title":"En bloc celiac axis resection for pancreatic cancer: classification of anatomical variants based on tumor extent","volume":"231","author":"Truty","year":"2020","journal-title":"J\u00a0Am Coll Surg"},{"issue":"2","key":"10.1016\/j.suc.2024.03.004_bib43","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jamcollsurg.2018.05.001","article-title":"Indications and perioperative outcomes for pancreatectomy with arterial resection","volume":"227","author":"Tee","year":"2018","journal-title":"J\u00a0Am Coll Surg"},{"issue":"1","key":"10.1016\/j.suc.2024.03.004_bib44","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13014-019-1309-x","article-title":"Ablative radiation therapy for locally advanced pancreatic cancer: techniques and results","volume":"14","author":"Reyngold","year":"2019","journal-title":"Radiat Oncol"},{"issue":"5","key":"10.1016\/j.suc.2024.03.004_bib45","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.surg.2017.11.027","article-title":"Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy","volume":"163","author":"Blair","year":"2018","journal-title":"Surgery"},{"issue":"2","key":"10.1016\/j.suc.2024.03.004_bib46","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/SLA.0000000000003284","article-title":"Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline\/locally advanced pancreatic cancer","volume":"273","author":"Truty","year":"2021","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.suc.2024.03.004_bib47","doi-asserted-by":"crossref","first-page":"18278","DOI":"10.1038\/s41598-020-74067-z","article-title":"Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems","volume":"10","author":"Matsuda","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.suc.2024.03.004_bib48","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41379-020-00683-9","article-title":"Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy","volume":"34","author":"Janssen","year":"2021","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.suc.2024.03.004_bib49","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.suc.2024.03.004_bib50","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.suc.2024.03.004_bib51","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.pan.2020.11.003","article-title":"Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma","volume":"21","author":"Wei","year":"2021","journal-title":"Pancreatology"},{"issue":"10","key":"10.1016\/j.suc.2024.03.004_bib52","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1245\/s10434-020-08427-4","article-title":"The sequential radiographic effects of preoperative chemotherapy and (chemo)radiation on tumor anatomy in patients with localized pancreatic cancer","volume":"27","author":"Perri","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.suc.2024.03.004_bib53","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/SLA.0000000000003442","article-title":"Radiographic and serologic predictors of pathologic major response to preoperative therapy for pancreatic cancer","volume":"273","author":"Perri","year":"2021","journal-title":"Ann Surg"},{"issue":"10","key":"10.1016\/j.suc.2024.03.004_bib54","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1007\/s00330-018-5410-6","article-title":"Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection","volume":"28","author":"Marchegiani","year":"2018","journal-title":"Eur Radiol"},{"issue":"8","key":"10.1016\/j.suc.2024.03.004_bib55","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/cncr.31251","article-title":"Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy","volume":"124","author":"Amer","year":"2018","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.suc.2024.03.004_bib56","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ejrad.2012.12.002","article-title":"An evaluation of the accuracy of CT when determining resectability of pancreatic head adenocarcinoma after neoadjuvant treatment","volume":"82","author":"Cassinotto","year":"2013","journal-title":"Eur J Radiol"},{"issue":"21","key":"10.1016\/j.suc.2024.03.004_bib57","article-title":"CT imaging assessment of pancreatic adenocarcinoma resectability after neoadjuvant therapy: current status and perspective on the use of radiomics","volume":"12","author":"Khasawneh","year":"2023","journal-title":"J\u00a0Clin Med"},{"issue":"7","key":"10.1016\/j.suc.2024.03.004_bib58","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1245\/s10434-012-2809-1","article-title":"CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy","volume":"20","author":"Hartwig","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.suc.2024.03.004_bib59","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.hpb.2019.06.012","article-title":"Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival. HPB","volume":"22","author":"Heger","year":"2020","journal-title":"(Oxford)"},{"key":"10.1016\/j.suc.2024.03.004_bib60","article-title":"Serum CEA as a prognostic marker for overall survival in patients with localized pancreatic adenocarcinoma and non-elevated CA19-9 levels treated with FOLFIRINOX as initial treatment: a taps consortium study","author":"Doppenberg","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.suc.2024.03.004_bib61","article-title":"For the Trans-Atlantic Pancreatic Surgery (TAPS) consortium. Impact of a non-therapeutic laparotomy in patients with locally advanced pancreatic cancer treated with induction (m)FOLFIRINOX: a TAPS consortium study","volume":"111","author":"Theijse RTS","year":"2024","journal-title":"Br J Surg"},{"issue":"2","key":"10.1016\/j.suc.2024.03.004_bib62","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1080\/1354750X.2020.1725786","article-title":"Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis","volume":"25","author":"van Manen","year":"2020","journal-title":"Biomarkers"},{"key":"10.1016\/j.suc.2024.03.004_bib63","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.2147\/OTT.S145708","article-title":"Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis","volume":"10","author":"Meng","year":"2017","journal-title":"OncoTargets Ther"},{"issue":"10","key":"10.1016\/j.suc.2024.03.004_bib64","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.ejso.2019.06.004","article-title":"Yield of staging laparoscopy before treatment of locally advanced pancreatic cancer to detect occult metastases","volume":"45","author":"Suker","year":"2019","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"10.1016\/j.suc.2024.03.004_bib65","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1007\/s00423-021-02199-5","article-title":"Laparoscopic biopsy and staging for locally advanced pancreatic cancer: experiences of 76 consecutive patients in a single institution","volume":"406","author":"Lin","year":"2021","journal-title":"Langenbecks Arch Surg"},{"issue":"5","key":"10.1016\/j.suc.2024.03.004_bib66","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jamcollsurg.2007.12.020","article-title":"Borderline resectable pancreatic cancer: the importance of this emerging stage of disease","volume":"206","author":"Katz","year":"2008","journal-title":"J\u00a0Am Coll Surg"},{"issue":"16","key":"10.1016\/j.suc.2024.03.004_bib67","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1002\/cncr.34273","article-title":"Preoperative therapy for pancreatic adenocarcinoma-precision beyond anatomy","volume":"128","author":"Seo","year":"2022","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.suc.2024.03.004_bib68","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.surg.2017.09.012","article-title":"Locally advanced pancreas cancer: Staging and goals of therapy","volume":"163","author":"Chatzizacharias","year":"2018","journal-title":"Surgery"},{"issue":"5","key":"10.1016\/j.suc.2024.03.004_bib69","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.surg.2020.07.024","article-title":"Commentary: Surgery for locally advanced pancreatic cancer after neoadjuvant therapy","volume":"169","author":"Evans","year":"2021","journal-title":"Surgery"},{"issue":"7","key":"10.1016\/j.suc.2024.03.004_bib70","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cam4.4527","article-title":"High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi-agent chemotherapy","volume":"11","author":"Hill","year":"2022","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.suc.2024.03.004_bib71","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00261-017-1290-5","article-title":"Pancreaticoduodenectomy with venous resection and reconstruction: current surgical techniques and associated postoperative imaging findings","volume":"43","author":"Javed","year":"2018","journal-title":"Abdom Radiol (NY)"},{"issue":"11","key":"10.1016\/j.suc.2024.03.004_bib72","doi-asserted-by":"crossref","first-page":"6211","DOI":"10.1245\/s10434-020-09568-2","article-title":"What Should Guide the Performance of Venous Resection During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma with Venous Contact?","volume":"28","author":"Navez","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.suc.2024.03.004_bib73","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11605-013-2374-3","article-title":"Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer","volume":"18","author":"Tran Cao","year":"2014","journal-title":"J\u00a0Gastrointest Surg"},{"issue":"6","key":"10.1016\/j.suc.2024.03.004_bib74","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/SLA.0b013e31823ac299","article-title":"Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis","volume":"254","author":"Mollberg","year":"2011","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.suc.2024.03.004_bib75","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1245\/s10434-008-9844-y","article-title":"Survival after pancreatectomy with major arterial resection and reconstruction","volume":"15","author":"Stitzenberg","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.suc.2024.03.004_bib76","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/j.hpb.2022.06.005","article-title":"Patency rates of hepatic arterial resection and revascularization in locally advanced pancreatic cancer","volume":"24","author":"Alva-Ruiz","year":"2022","journal-title":"HPB (Oxford)"},{"issue":"4","key":"10.1016\/j.suc.2024.03.004_bib77","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1245\/s10434-021-11202-8","volume":"29","author":"Hill","year":"2022","journal-title":"Ann Surg Oncol"}],"container-title":["Surgical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039610924000392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039610924000392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T08:09:50Z","timestamp":1725437390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039610924000392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0039610924000392"],"URL":"https:\/\/doi.org\/10.1016\/j.suc.2024.03.004","relation":{},"ISSN":["0039-6109"],"issn-type":[{"value":"0039-6109","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Locally Advanced Pancreas Cancer, Is There a Role for Surgery?","name":"articletitle","label":"Article Title"},{"value":"Surgical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.suc.2024.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}